Human α-galactosidase a mutants : Priceless tools to develop novel therapies for fabry disease

Rosa Mendoza, José Luis Corchero Nieto, Andrea Modrego, Marilla Amaranto, Agustina Godino, José Luis Barra

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

10 Cites (Scopus)

Resum

Fabry disease (FD) is a lysosomal storage disease caused by mutations in the gene for the α-galactosidase A (GLA) enzyme. The absence of the enzyme or its activity results in the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in different tissues, leading to a wide range of clinical manifestations. More than 1000 natural variants have been described in the GLA gene, most of them affecting proper protein folding and enzymatic activity. Currently, FD is treated by enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT). How-ever, as both approaches show specific drawbacks, new strategies (such as new forms of ERT, or-gan/cell transplant, substrate reduction therapy, or gene therapy) are under extensive study. In this review, we summarize GLA mutants described so far and discuss their putative application for the development of novel drugs for the treatment of FD. Unfavorable mutants with lower activities and stabilities than wild-type enzymes could serve as tools for the development of new pharmacological chaperones. On the other hand, GLA mutants showing improved enzymatic activity have been identified and produced in vitro. Such mutants could overcome several complications associated with current ERT, as lower-dose infusions of these mutants could achieve a therapeutic effect equiv-alent to that of the wild-type enzyme.
Idioma originalEnglish
RevistaInternational Journal of Molecular Sciences
Volum22
Número12
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Human α-galactosidase a mutants : Priceless tools to develop novel therapies for fabry disease'. Junts formen un fingerprint únic.

Com citar-ho